>

Gwen Melincoff - KAMADA Director

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 40px;;'>KMD</div>
KMDA -- Israel Stock  

ILA 2,071  34.00  1.67%

  Director
Ms. Gwen A. Melincoff serves as Director of the Company. Ms. Melincoff is currently an advisor to Phase 1 Ventures, an accelerator startup program, and Verge Genomics, a privatelyheld life sciences company focused on the discovery and development of treatments for neurodegenerative diseases. From August 2014 to September 2016, she served as Vice President of Business Development at BTG International Inc., a UKbased specialist healthcare company. From 2004 to 2013, Ms. Melincoff was Senior Vice President of Business Development at Shire Pharmaceuticals. Additionally, from 2010 to 2013, she led the company Strategic Investment Group . Prior to joining Shire, Ms. Melincoff held managerial and business development positions at various pharmaceutical companies, including Adolor Corporationrationration
Age: 66  Director Since 2017      
(972) 8 9406472  www.kamada.com
Melincoff has served as a board member/board observer at Tobira Therapeutics, DBV Technologies, AM Pharma, ArmaGen Technologies, Promethera Biosciences, Naurex Inc., and Enterome.

Gwen Melincoff Latest Insider Activity

Management Efficiency

The company has accumulated 5.75 M in total debt with debt to equity ratio (D/E) of 4.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. KAMADA has Current Ratio of 6.02 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Dov HershbergCOMPUGEN
2010
Eli ZangvilEVOGENE LTD
2006
Philip SerlinKITOV PHARMA LTD
2013
Nir PelegSOLEGREEN LTD
2017
Avner NavehSOLEGREEN LTD
Erez BalashaSOLEGREEN LTD
2018
Oded ShoseyovEVOGENE LTD
2018
Yair AharonowitzCOMPUGEN
2007
Adrian PercyEVOGENE LTD
2019
Joshua ShemerCOMPUGEN
2007
Shmuel PinchasSOLEGREEN LTD
2010
Kinneret SavitskyCOMPUGEN
2018
Itai CohenSOLEGREEN LTD
2017
Arie WeberKITOV PHARMA LTD
2017
Chava ToaffSOLEGREEN LTD
2018
Ido AgmonKITOV PHARMA LTD
2016
Amos BarShalevPROTALIX BIOTHERAP
2008
Shlomo FedidaSOLEGREEN LTD
2018
Ran TzrorKITOV PHARMA LTD
2017
Leon RecanatiEVOGENE LTD
2005
Yodfat BuchrisPROTALIX BIOTHERAP
2007

Company Summary

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. Kamada Ltd. was founded in 1990 and is headquartered in Rehovot, Israel. KAMADA operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 429 people.KAMADA (KMDA) is traded on Tel Aviv Stock Exchange in Israel and employs 429 people.

KAMADA Leadership Team

Pnina Strauss, Vice President - Inhalation programs & IPView
Itzhak Krinsky, DirectorView
Barak Bashari, Vice President - OperationsView
Eran Schenker, Vice President - Medical DirectorView
Tuvia Shoham, Independent DirectorView
Michal Stein, Vice President and Medical Director for ImmunologyView
Shani Dotan, Vice President of Human ResourcesView
Liliana Bar, VP of RandDView
Yael Brenner, Vice President - QualityView
Abraham Havron, Independent DirectorView
Asaf Frumerman, DirectorView
Ruth Wolfson, Senior Vice President - Scientific AffairsView
Shmuel Rubinstein, DirectorView
Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary DiseasesView
Michael Berelowitz, DirectorView
David Tsur, Co-Founder and Deputy Executive ChairmanView
Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&DView
Leon Recanati, Chairman of the BoardView
Gil Efron, CFO, Principal Accounting Officer and Deputy CEOView
Jonathan Hahn, DirectorView
Eran Schenkar, Vice President - Medical DirectorView
Gwen Melincoff, DirectorView
Chaime Orlev, Chief Financial OfficerView
Michal Ayalon, Vice President - Research & DevelopmentView
Amir London, Chief Executive OfficerView
Estery GilozRan, Independent DirectorView
Reuven Behar, DirectorView
Eitan Kyiet, Vice President - Business DevelopmentView
Ziv Kop, DirectorView

Stock Performance Indicators

Did you try this?

Run Fundamental Analysis Now

   

Fundamental Analysis

View fundamental data based on most recent published financial statements
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page